Resapp Health Ltd
ASX:RAP
Intrinsic Value
ResApp Health Ltd. engages in the research and commercial development of ResApp technology for the purpose of providing health care solutions for respiratory disease. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of RAP.
Resapp Health Ltd's market capitalization is 176.2m AUD.
RAP stock price is 0.205 AUD.
RAP.
RAP. Open DCF Valuation
RAP. Open Relative Valuation
RAP has upside potential of 17% compared to the average analyst price target.
Open Wall St Estimates
RAP's long-term assets (6m AUD) exceed its long-term liabilties (5m AUD).
RAP's ROIC (Return on Invested Capital) has increased in the last 3 years from -324% to -317%, and is approaching profitability.
RAP's short-term liabilties (5m AUD) exceed its short-term assets (4m AUD).
RAP's ROE (Return on Equity) has significantly decreased in the last 3 years from -151% to -171%, and is approaching profitability.
RAP's Revenue has grown by an exceptional 2 809% over the past 12 months.
RAP has negative Operating Income for the last twelve months.
RAP has negative Net Income for the last twelve months.
RAP's ROE (Return on Equity) for the past 12 months is negative and is equal to -171%.
RAP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -317%.
RAP has negative Free Cash Flow for the last twelve months.
RAP has negative three-year average ROE (Return on Equity): -121%. The company is not efficient at transforming stockholders' equity into net income.
RAP has negative three-year average ROIC (Return on Invested Capital): -118%. The company is not efficient at using invested capital to generate operating income.
RAP's D/E (Debt to Equity) is very low and is equal to 0.
RAP's Altman Z-Score is very low and is equal to -1.24.
Fundamental Analysis
Resapp Health Ltd
Balance Sheet Decomposition
Resapp Health Ltd
| Current Assets | 4.1m |
| Cash & Short-Term Investments | 2.4m |
| Receivables | 1.6m |
| Other Current Assets | 88.1k |
| Non-Current Assets | 1.7m |
| PP&E | 103.6k |
| Intangibles | 1.6m |
| Other Non-Current Assets | 10 |
| Current Liabilities | 4.8m |
| Accounts Payable | 1.2m |
| Accrued Liabilities | 1.2m |
| Other Current Liabilities | 2.3m |
| Non-Current Liabilities | 345.7k |
| Other Non-Current Liabilities | 345.7k |
Earnings Waterfall
Resapp Health Ltd
|
Revenue
|
2.5m
AUD
|
|
Operating Expenses
|
-9.5m
AUD
|
|
Operating Income
|
-6.9m
AUD
|
|
Other Expenses
|
-150k
AUD
|
|
Net Income
|
-7.1m
AUD
|
Free Cash Flow Analysis
Resapp Health Ltd
What is Free Cash Flow?
RAP Profitability Score
Profitability Due Diligence
Resapp Health Ltd's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Resapp Health Ltd's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
RAP Solvency Score
Solvency Due Diligence
Resapp Health Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Resapp Health Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RAP Price Targets Summary
Resapp Health Ltd
According to Wall Street analysts, the average 1-year price target for
RAP
is 0.24 AUD
.
Shareholder Return
RAP Price
Resapp Health Ltd
| Average Annual Return | -13.22% |
| Standard Deviation of Annual Returns | 72.78% |
| Max Drawdown | -90% |
| Market Capitalization | 176.2m AUD |
| Shares Outstanding | 859 697 077 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Resapp Health Ltd
Country
Industry
Market Cap
Dividend Yield
Description
ResApp Health Ltd. engages in the research and commercial development of ResApp technology for the purpose of providing health care solutions for respiratory disease. The company is headquartered in Brisbane, Queensland. The company went IPO on 2005-01-12. The Company’s digital healthcare solutions assists doctors and patients to diagnose and manage respiratory disease. The firm has developed a platform for diagnosing respiratory disease using the sound of a patient’s cough. The platform is based on sound alone and does not require physical contact with the patient. With smartphones integrating microphones, the platform can be delivered without the need for additional hardware. The firm has developed smartphone-based machine learning algorithms, which can identify exacerbations in patients with asthma or COPD. The company also has ongoing clinical programs investigating the use of these techniques to measure exacerbation severity and lung function. The firm has developed an obstructive sleep aponia screening test that uses overnight breathing and snoring sounds recorded on a smartphone placed on the bedside table.
You don't have any saved screeners yet
